Researchers Find Differences in Pancreatic Tumours, Pointing Toward More Personalised Care

A study at the University of Cincinnati in the United States has found differences in pancreatic tumours that could help explain why this cancer behaves differently in different patients. According to the researchers, those differences could open a path toward treatment plans tailored to individual patients.
The researchers examined 22 pancreatic tumours from patients of different racial backgrounds across the United States. Seven of the patients were Black and 15 were non-African American. The team looked for differences in the cancer cells and in how the immune system responds to them. The findings were published in the journal Cancer Research.
The study found that tumours from Black patients had fewer of the most common type of pancreatic cancer cells. Instead, they contained more cells with a mix of different characteristics. The researchers said some of those cell characteristics have been associated with drug resistance, but the study did not establish whether they affected patients' treatment outcomes.
Tumours from Black patients also contained more B cells, a type of immune cell, and larger clusters of immune cells. The researchers found signs that some B cells may suppress the body's response to cancer, although they said the significance of these differences is unclear.
No significant differences were found between the groups in the major genetic changes known to drive the disease. According to the researchers, pancreatic cancer is approximately 20 percent more likely to develop in Black Americans than in non-African Americans.
The study's lead author, Nina Steele, is an assistant professor at the University of Cincinnati's College of Medicine. She said that ignoring diverse ancestry in medical research leaves blind spots in the search for a cure. In her view, the study highlights the importance of including patients from different backgrounds in cancer research.
Dr Raymond Wadlow, a gastrointestinal medical oncologist at Inova Schar Cancer Institute in Virginia, was not involved in the study. He said using immunotherapy to help the immune system attack the disease has been particularly challenging in pancreatic cancer, because the tumour subverts the immune system so that it works for the tumour instead of for the body.
Wadlow also said pancreatic cancers can share major DNA mutations while differing considerably in how their cells behave and interact with nearby immune cells and surrounding tissue. In his words, the cancer cell itself is only part of the story; the surrounding immune cells and tissue may affect how a tumour behaves and responds to treatment.
The researchers also noted the study's limitations. They have not established how the mixed-characteristic tumour cells affect survival, or whether they respond differently to standard chemotherapy. The team said pancreatic tissue from people without cancer also needs to be studied to better understand when these differences develop.
Wadlow cautioned that the findings are still a long way from changing patient care. He noted that race and genetic ancestry do not fully account for the environmental, socioeconomic and biological factors that could explain the findings. Larger studies involving patients from diverse backgrounds are needed to determine whether these differences affect treatment outcomes or survival.
The research was funded in part by the National Cancer Institute. Wadlow encouraged newly diagnosed patients to ask about hereditary genetic testing, which can identify inherited mutations that may also affect relatives, so family members can be tested as well.




